AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06411418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pipeline™ Flex Embolization Device with Shield Technology™
Description: The Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments. The Pipeline™ Flex Embolization Device with Shield Technology™ is also indicated for use in the internal carotid artery up to the terminus for the endovascular treatment of adults (22 years of age or older) with small and medium wide-necked (neck width ≥ 4 mm or dome-to-neck ratio \< 2) saccular or fusiform intracranial aneurysm (IAs) arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 5.0 mm.
Study NCT05145361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B001 injection
Description: B001 injection 50mg/5mL Intravenous solution
Study NCT05145361 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 5mL Intravenous solution
Study NCT05440448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch-free occlusion therapy
Description: Use of filters in glasses to provide occlusion therapy
Study NCT05440448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesive patch
Description: Standard-of-care occlusion therapy with an adhesive patch
Study NCT05507879 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05507879 — intervention group
Intervention type: OTHER
Intervention: Electronic Medical Record
Description: Review of medical records
Study NCT05353257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W
Study NCT05353257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin/cisplatin-etoposide
Description: Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice.~Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice.
Study NCT05353257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin/cisplatin-etoposide
Description: Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice.~Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice.
Study NCT05353257 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: Standard Thoracic Radiotherapy
Study NCT05353257 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Thoracic radiotherapy
Description: Standard Thoracic Radiotherapy
Study NCT05353257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Q3W
Study NCT05353257 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation (PCI)
Description: PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
Study NCT05353257 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Prophylactic Cranial Irradiation (PCI)
Description: PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
Study NCT05008484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach
Study NCT05008484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2000IU oral vitamin D supplementation daily for 9 months
Study NCT05008484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive movement
Description: Subjects will perform simple passive movement exercise for their legs while sitting in their wheelchairs at their home. The frequency of the training will be twice weekly. .
Study NCT04982497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game based intervention
Description: The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated prevention program based on the model by Lewinsohn et al. (1985). The cognitive stimulation component is based on cognitive reserve (Tucker \& Stern, 2011) and neuroplasticity (Shapiro, 2001), the cognitive stimulation model by Spector et al. (2006), and the causes of age-related memory failures (Light, 1991) (e.g., decrease in the processing resources, semantic coding deficit, difficulties in deliberate information retrieval). The healthy habits promotion component is based on the social learning and social cognitive theories (Bandura, 1986; Spiegler, 2016).
Study NCT04982497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The active control group will have access to a platform of online therapeutically inactive information related to active aging.
Study NCT06138925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of walking
Description: 3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at different speeds (slow, comfortable and fast)
Study NCT06138925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of running
Description: analysis of running on flat ground at different speeds (comfortable and fast)
Study NCT06138925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of walking
Description: 3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at spontaneous speed (comfortable).
Study NCT06391853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h.
Study NCT06391853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h.
Study NCT05500170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Nicotinamide riboside (NR) is a form of vitamin B3, which is found in fruits, vegetables, meat, and milk. NR is converted into nicotinamide adenosine dinucleotide NAD+. Low NAD+ levels have been linked to Alzheimer's disease and sleep disturbances.
Study NCT05500170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pill will contain micro cellulose powder.
Study NCT04243941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-HBED-CC-PSMA
Description: Radioactive tracer used during imaging to help detect PSMA expressing tumor cells
Study NCT05011292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video about SCB
Description: 3-4 minutes video about SCB.
Study NCT05011292 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey on child feeding and related knowledge and practices
Description: Short survey about infant feeding practices (3-4 minutes). No identifying information will be collected. The general scope of topics covered in the surveys will be attitudes toward the sugar-containing beverage reduction (SCB) videos played at the clinic as well as SCB knowledge and practices of parents and their children.
Study NCT05011292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey on child feeding and related knowledge and practices
Description: Short survey about infant feeding practices (3-4 minutes). No identifying information will be collected. The general scope of topics covered in the surveys will be attitudes toward the sugar-containing beverage reduction (SCB) videos played at the clinic as well as SCB knowledge and practices of parents and their children.
Study NCT05011292 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Video other than SCB
Description: Educational video about a topic other than infant SCB consumption.
Study NCT05782881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phone calls and encouraging patients' lifestyle change and medication adherence
Description: Use some methods to strictly intervene blood glucose , blood pressure and blood lipids for protocol treatment group people.
Study NCT05782881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin
Description: Treatment and management according to the guidelines
Study NCT05782881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Treatment and management according to the guidelines
Study NCT05998629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels
Description: a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels
Study NCT05998629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care laboratory procedure for measurement of sweat
Description: a skin-interface sweat measurement using a smart-watch type device
Study NCT05005897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin
Description: Intramuscular injection of 400 µg cobalamin to children with elevated thcy at enrollment
Study NCT05390593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS-1800
Description: Participants in the 1800-pulse intermittent TBS (iTBS-1800) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.
Study NCT05390593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS-1200
Description: Participants in the 1200-pulse intermittent TBS (iTBS-1200) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.
Study NCT04897360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased breathing
Description: hyperventilation to lower ETCO2
Study NCT06530732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Cervical lymphatlc-Venous Anastomosis Surgery
Description: Cervical deep lymphatic-venous anastomosis (dcLVA) can promote the flow of cerebrospinal fluid within the glymphatic system. The procedure involves connecting deep cervical lymphatic vessels to veins, reducing pressure on lymph nodes and allowing lymphatic fluid from high-pressure vessels to flow into the lower-pressure venous system. This surgical intervention enhances the clearance of waste in the glymphatic system, particularly amyloid-beta (Aβ) and tau proteins. By facilitating the removal of these AD-associated proteins from the brain, dcLVA can reduce local tissue fibrosis and cervical nerve compression, potentially reversing degenerative changes, slowing disease progression, and improving the quality of life for AD patients.
Study NCT06530732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lecanemab
Description: The newly approved anti-beta-amyloid (Aβ) monoclonal antibody Lecanemab can delay AD progression but is only suitable for patients in the early stages. For those with moderate to severe AD, Lecanemab is not effective.
Study NCT06415812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evolutionary Systems Therapy
Description: Evolutionary Systems Therapy is an individual form of psychotherapy (talk therapy) that has been previously tested trough a randomized controlled trial and a few cases series, confirming its feasibility and safety.
Study NCT05312632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide Mesilate
Description: Safinamide Mesilate oral tablets.
Study NCT05617066 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: With the cognitive behavioral therapy will work on different aspects for coping and tools psychological stress.
Study NCT04149977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy with pressure cuff
Description: 6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a cuff around the affected leg during the exercises.
Study NCT04149977 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical Therapy with placebo pressure cuff
Description: 6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a pressure cuff around the affected leg during the exercises. The pressure cuff will have 50% of the pressure that will be considered effective.
Study NCT04897360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sharpened Romberg test (SRT)
Description: Balance test conducted by standing with feet in front of each other, heel-to-toe in line while the right hand is on the left shoulder and the left hand is on the right shoulder.
Study NCT06436482 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Placing the probe of OCT in RB10c through the working channel of bronchoscope for real time dynamic scanning and collecting OCT parameters from participants in different groups.
Study NCT05174221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezagitamab
Description: TAK-079 subcutaneous injection.
Study NCT06319508 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.
Study NCT06319508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.
Study NCT06319508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06319508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Once a day.
Study NCT06319508 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. 1 milliliter of normal saline will be used for injection.
Study NCT04597671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is used as standard of care
Study NCT04597671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab is used as standard of care
Study NCT04597671 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose PCI
Description: PCI will be given concurrently with durvalumab. PCI will be given to a dose of 15 Gy in 10 fractions
Study NCT04911491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMST
Description: Inspiratory muscle strength training (IMST) is a form of physical training that utilizes the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device.
Study NCT04911491 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: Repeated inhalations against a low resistance will be performed using a handheld device.
Study NCT06275308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation manipulation
Description: Effects of ventilation manipulation to achieve desired levels of end tidal carbon dioxide
Study NCT05636618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT-α-NET
Description: Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered every 8 weeks for a maximum of four doses
Study NCT05636618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT-α-NET
Description: Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered at the RPh2D and schedule determined in Phase I dose escalation
Study NCT05348577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capivasertib
Description: 320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle.~Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
Study NCT05348577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
Study NCT05348577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docetaxel
Description: Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
Study NCT05348577 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
Study NCT05447195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN008
Description: Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given CAN008 + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the CAN008+TMZ maintenance therapy period in which subjects in both groups are given CAN008+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given CAN008 IV infusion weekly until disease progression.